Patents Assigned to PACT PHARMA, INC.
  • Primary cell gene editing
    Patent number: 10711283
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: July 14, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • PRIMARY CELL GENE EDITING
    Publication number: 20200181650
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 11, 2020
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Primary cell gene editing
    Patent number: 10676758
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: June 9, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • PRIMARY CELL GENE EDITING
    Publication number: 20200165634
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: February 5, 2020
    Publication date: May 28, 2020
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Primary cell gene editing
    Patent number: 10584357
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: March 10, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • PEPTIDE-MHC COMPACTS
    Publication number: 20200062819
    Abstract: Disclosed herein are antigenic peptide-MHC molecules, termed comPACTs, and methods of producing such molecules. Also disclosed herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells.
    Type: Application
    Filed: November 8, 2019
    Publication date: February 27, 2020
    Applicant: PACT PHARMA, INC.
    Inventors: Olivier Dalmas, Zheng Pan, Michael Bethune, Songming Peng
  • Primary cell gene editing
    Patent number: 10550406
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: February 4, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • PRIMARY CELL GENE EDITING
    Publication number: 20190376086
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: August 27, 2019
    Publication date: December 12, 2019
    Applicant: PACT PHARMA, INC.
    Inventors: KYLE JACOBY, ALEX FRANZUSOFF
  • PRIMARY CELL GENE EDITING
    Publication number: 20190376091
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: August 27, 2019
    Publication date: December 12, 2019
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff